POLBF (Poolbeg Pharma) Tax Provision: $0.11 Mil (TTM As of Dec. 2025)


What is Poolbeg Pharma Tax Provision?

Poolbeg Pharma POLBF Tax Provision is $0.11 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Poolbeg Pharma's tax provision for the six months ended in Dec. 2025 was $0.03 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2025 was $0.11 Mil.

Poolbeg Pharma Tax Provision Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma Tax Provision Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
0.00 0.11 0.73 0.20 0.11

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Tax Provision Get a 7-Day Free Trial Premium Member Only 0.73 0.03 0.16 0.08 0.03

Poolbeg Pharma Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $0.11 Mil mean?
Poolbeg Pharma (POLBF) has a Tax Provision of $0.11 Mil as of Dec. 2025. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Poolbeg Pharma and its competitors.
Is Poolbeg Pharma's Tax Provision too high?
Poolbeg Pharma's current Tax Provision is $0.11 Mil.
How does Poolbeg Pharma's Tax Provision compare to VRTX and REGN?
Poolbeg Pharma's Tax Provision of $0.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Poolbeg Pharma and its competitors. Poolbeg Pharma's current Tax Provision is $0.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Tax Provision of $0.11 Mil. The current Tax Provision is $0.11 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Tax Provision is $0.11 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.